cagrilintide and tirzepatide blend is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese had ≥1 weight-related complication, individuals assigned to a combination cagrilintide tirzepatide blend (10mg vials)

Preclinical studies indicate potential roles in: Supporting healthy fat metabolism and reduction of adipogenesis Improving insulin sensitivity in metabolic research models Enhancing NAD+ salvage pathway efficiency Exploring effects on energy homeostasis and longevity pathways These findings remain preliminary and confined to laboratory and animal models

Interpreting the modest early effect as the drug isnt working and reacting by jumping steps is exactly the mistake the ladder is built to prevent

PMID: [21030672] A peer-reviewed receptor-expression study in tendon fibroblast BPC-157 research Molecules, 2014

they don't replace it